Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
7.11
-0.41 (-5.45%)
Feb 21, 2025, 4:00 PM EST - Market closed
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Atara Biotherapeutics stock have an average target of 25.7, with a low estimate of 11 and a high estimate of 57.5. The average target predicts an increase of 261.46% from the current stock price of 7.11.
Analyst Consensus: Buy
* Price targets were last updated on Jan 17, 2025.
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 6 | 6 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +139.10% | Jan 17, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +251.62% | Dec 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 → $21 | Strong Buy | Maintains | $13 → $21 | +195.36% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
118.42M
from 8.57M
Increased by 1,281.31%
Revenue Next Year
92.47M
from 118.42M
Decreased by -21.92%
EPS This Year
-2.27
from -65.18
EPS Next Year
-9.34
from -2.27
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 143.2M | 162.8M | 134.4M | |||
| Avg | 118.4M | 92.5M | 72.8M | |||
| Low | 94.5M | 54.9M | 2.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1,570.4% | 37.4% | 45.4% | |||
| Avg | 1,281.3% | -21.9% | -21.3% | |||
| Low | 1,002.0% | -53.7% | -96.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.34 | -8.36 | -1.24 | ||
| Avg | -2.27 | -9.34 | -1.68 | ||
| Low | -2.19 | -10.25 | -2.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.